Baltic biotech attracts investors
Enlarge image


Baltic biotech attracts investors

17.09.2012 - The very first Life Science Baltics 2012 attracted twice as many visitors than anticipated. Investors are lured by EU funds, low cost and qualified staff.

The very first Life Science Baltics conference almost 800 life science professionals visiting Vilnius. „That’s almost twice than we expected“, Jelena Suchodumceva, Senior Project Manager at Enterprise Lithuania, told EuroBiotechNews at the conference. According to the organisers from the governmental agency, more than 80% of the attendants came from non-Baltic states such as Israel, Canada, the US or EU member states. A trade fair showcasing the offerings of more than 40 companies and over 100 pre-scheduled B2B meetings reflected the huge interest to invest in the Baltic scene.

At the conference, ThermoFisher Scientific stated it will inaugurate a €16m research and production facility next week on the grounds of former Lithuanian Fermantas AB. Furthermore, Biotechpharma UAB received an €11m cash injection from EU structural funds. The money helped the Lithuanian CMO to build a state-of-the-art biopharmaceutical facility, which will become fully operational next year at Santara Valley, a brand-new life sciences-IT incubator in the country’s capital. The cluster is one of 5 high-tech valleys supported by the Lithuanian government with investments of €400m.

Prof. Dr. Vladas Bumelis, Chairman of Biotechpharma and Lithuanian biotech mastermind, said at the conference that investors are attracted by the strong knowledge base, low cost of goods and the governmental commitment to support the life sciences sector. To become a big fish within the life science scene, however, it would be essential for the many but small firms in the Baltic region to swim in formation. According to Enterprise Lithuania, the country’s life sciences industry has been skyrocketing over the last two decades with an annual growth rate of 22%, and over 80% of the production being exported. Last year, exports from the life sciences sector amounted to €276.2m. Its main export markets were Sweden (21.1% of the total); Germany (10.9%); Italy (8.1%); UK (6.%); Denmark (6.7%); Russia (4.7%); Norway (4.6%); Poland (4.3%); France (4%); and Latvia (2.7%).



26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • EVOCUTIS (UK)0.12 GBP33.33%
  • EPIGENOMICS (D)2.65 EUR17.26%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • SERODUS (N)2.18 NOK-18.35%
  • DEINOVE (F)5.14 EUR-17.63%


  • PLETHORA (UK)5.50 GBP91.0%
  • PROTHENA PLC (IE)75.31 USD46.2%


  • EPIGENOMICS (D)2.65 EUR-44.0%
  • RENEURON (UK)2.88 GBP-25.8%


  • KARO BIO (S)37.90 SEK5314.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.60 EUR260.1%


  • BIOTEST (D)15.31 EUR-81.0%
  • NEOVACS (F)0.80 EUR-76.5%

No liability assumed, Date: 29.11.2015